checkAd

IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting - Seite 2


Preliminary Overall Survival

  • 10 patients have now completed therapy.
  • Overall survival (OS) on this interim analysis shows median 15.97 months to date, with three patients exhibiting stable disease at day 135 and two with stable disease at day 180.

Figure 1: Overall survival (to date) indicates a median 15.97 months OS, with three patients exhibiting stable disease at day 135 and two with stable disease at day 180. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fa71c8e9-45c9-47a4 ...

Dr. Colin Hayward, Chief Medical Officer at Telix said, “Whilst a single arm study, the overall survival demonstrated in this initial patient population is encouraging. GBM has a median survival from initial diagnosis of 12-15 months, so the prospect of potentially improved OS in the second line setting warrants further investigation in a larger patient cohort, including earlier stage patients.”

Dr. Josef Pichler, Kepler University Hospital, Austria, Principal Investigator in the study added, “These peer-reviewed data confirm that TLX101 in combination with XRT is safe and well-tolerated in patients with recurrent GBM, for whom there is an extremely poor prognosis and few treatment options. I look forward to evaluating this investigational asset in front-line therapy, to accelerate development in this underserved disease area with such high unmet medical need.”

Dr. Arthur Braat, UMC Utrecht, The Netherlands continued, “The results of the IPAX-1 study of TLX101 in combination with XRT are encouraging both in terms of confirming safety and tolerability, and initial signs of efficacy in patients with recurrent GBM. The promising overall survival and anti-tumour response we observe in longitudinal imaging supports the decision to progress this candidate into study in an earlier line of therapy.”

About TLX101
TLX101 is a systemically administered molecularly-targeted radiation (MTR) investigational therapeutic product that targets L-type amino acid transporter 1 (LAT-1), which is typically highly expressed in GBM. TLX101 has been granted orphan drug designation in the US and Europe.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Switzerland, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Seite 2 von 3



0 Kommentare
Nachrichtenquelle: globenewswire
20.10.2021, 00:12  |  107   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting - Seite 2 MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) - Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 (4-L-[131I] …

Nachrichten des Autors

Titel
Titel
Titel
Titel